ArticleHealth care science2026
Combined Detection of Preoperative Serum Calcitonin and Carcinoembryonic Antigen in Medullary Thyroid Carcinoma: A Retrospective Multicenter Cohort Study.
Article in Health care science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The aim of this study was to investigate the clinical value of combined detection of preoperative serum calcitonin (Ctn) and carcinoembryonic antigen (CEA) for diagnosing medullary thyroid carcinoma (MTC), as well as predicting lymph node metastases and prognosis, compared with the value of detection of either marker alone. Methods: This retrospective multicenter cohort study included patients with thyroid nodules who underwent preoperative measurements of serum Ctn and CEA at six medical centers between 2012 and 2024. Receiver operating characteristic (ROC) curves were analyzed to compare the diagnostic performances of Ctn, CEA, and their combination. Results: A total of 13,272 patients were included in the study, comprising 115 with MTC, 10,845 with papillary thyroid carcinoma, and 2312 with benign nodules. For diagnosing MTC, the area under the ROC curve (AUC) values for Ctn and CEA alone were 0.992 and 0.983, respectively, while the combination of the two markers achieved the highest AUC of 0.999. Ctn had a higher positive predictive value (PPV) for MTC diagnosis than CEA (51% vs. 31%), and the combination did not improve the PPV (46%) compared with Ctn alone. For predicting cervical and lateral neck lymph node metastases in MTC, the combination had a higher AUC than Ctn or CEA alone (0.735 vs. 0.708 vs. 0.655 and 0.769 vs. 0.707 vs. 0.675). The combination also had a higher AUC for predicting recurrence than Ctn or CEA alone (0.734 vs. 0.642 vs. 0.611). Conclusions: Compared with the detection of either marker alone, the combined detection of Ctn and CEA improved the diagnostic accuracy for MTC but did not enhance the PPV. The combined detection also improved the predictive accuracy for cervical and lateral lymph node metastases and disease recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.